Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Omeros Corporation

OMER ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$18.88

▼ -3.82%

Market Cap $1.37B · Vol 338.37K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

13.03

FWD: 19.99

Market Cap

$1.37B

Small Cap

Div Yield

N/A

EPS Growth

+1,750.00%

YoY

RSI (14)

32.65

Momentum

Beta

2.95

vs Market

52W High

$21.22

11.03% below

52W Low

$4.06

365.60% above

Volume

338.37K

Avg 481.31K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

95.92%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Omeros Corporation (OMER) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OMER pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.00%

+3.28%

+88.61%

+65.91%

YTD

+9.93%

+350.60%

+731.72%

+155.83%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-4,808,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-0.93% · N/A

P/E Ratio	13.03
Forward P/E (FY1)	19.99
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+1,750.00%
Outstanding Shares	72.39M

Technical Indicators

50-Day SMA	$18.00
200-Day SMA	$13.31
RSI (14)	32.65
Beta	2.95
52-Week High	$21.22
52-Week Low	$4.06

Volume Today	338.37K
Avg Daily Volume (30D)	481.31K
Relative Volume	0.70x
Volatility (10D)	36.18
Volatility (30D)	54.40
Free Float	95.92%

Analyst Consensus

BUY

Current Price $18.88

Mean Target $36.67

52W Low$4.06 52W High$21.22

Current

Target

$4.06 $21.22

Current Analyst target

+94.21% upside potential · 3 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SPJH21

ISINUS6821431029

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -0.19% ARGX.BR argenx SE -1.99% ARGX argenx SE -1.19% 2269.HK WuXi Biologics (Cayman) Inc. -2.66% GMAB Genmab A/S -2.14%

Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.